PROLOR Biotech Inc

PROLOR Biotech — 5th Diabetes Drug Discovery & Development Conference (April 2012)

14 slides from PROLOR Biotech's conference presentation, Apr 19, 2012

  1. Slide 1: Long Acting Reversible PEGylated Oxyntomodulin - MOD-6030

    Slide 1: Long Acting Reversible PEGylated Oxyntomodulin - MOD-6030

    Long Acting Reversible PEGylated Oxyntomodulin - MOD - 6030 Apr 2012 5th Diabetes Drug Discovery & Development Conference

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward - looking statements, including statements regarding the results of current studies and pre - clinical experiments and the effectiveness of PROLOR’s long - acting protein programs and are made pursuant to the safe harbour provisions of the Pri

  3. Slide 3: PROLOR's Expected Product Pipeline

    Slide 3: PROLOR's Expected Product Pipeline

    Indication Product Market Size Preclin. Ph I Ph II Ph III Growth Disorders hGH - CTP $3B Hemophilia Factor VIIa - CTP $1.3B 2 / week injection Factor IX - CTP $0.7B 1 /week injection Diabetes Type II & Obesity GLP1/Glucagon dual receptor agonist $2B 1/week injection PROLOR’s Expected Product Pipelin

  4. Slide 4: Reversible PEGylation - Mechanism

    Slide 4: Reversible PEGylation - Mechanism

    4 Reversible PEGylation - Mechanism 4 PEG chain too large → lost activity • PEG chain hydrolyzes at controlled PK profile • Authentic drug released • Unique linkers, patent protected Native peptide - Fully Active + H 2 0 Physiological hydrolysis pH 7; 37 o C PEG chain PEG chain Hydrolyzed Linker Hyd

  5. Slide 5: REV-PEG Technology Main Advantages

    Slide 5: REV-PEG Technology Main Advantages

    REV - PEG Technology Main Advantages: □ Long lasting fully active authentic peptide □ 1 st order hydrolysis reaction (slow, supporting predictable pharmacokinetic pattern) □ Dose reduction □ Technology applicable for all peptides and a wide range of small molecules. □ Allows development of long acti

  6. Slide 6: Oxyntomodulin – Nature's Appetite Control Mechanism

    Slide 6: Oxyntomodulin – Nature's Appetite Control Mechanism

    REV - PEG Technology main advantages: 6 Oxyntomodulin – Nature’s Appetite Control Mechanism • Natural appetite suppressor • Oxyntomodulin is a dual GLP - 1 /Glucagon receptor agonist • Secreted by the digestive system following food intake and induces satiety in the brain • Crosses blood - brain bar

  7. Slide 7: Long-Acting GLP-1/Glucagon Dual Receptor Agonist versus Native Oxyntomodulin

    Slide 7: Long-Acting GLP-1/Glucagon Dual Receptor Agonist versus Native Oxyntomodulin

    MOD - 6030 — Long - Acting GLP - 1/Glucagon Dual Receptor Agonist versus Native Oxyntomodulin: Previous 3 rd party oxyntomodulin studies:  Animals (mice, rats): 2 injections per day  Glycemic control  Food intake reduced  Weight loss observed  Humans: 3 injections per day  Weight Loss of 0.5 k

  8. Slide 8: Feasibility Study in DIO Mice Model Study Design

    Slide 8: Feasibility Study in DIO Mice Model Study Design

    Feasibility Study in DIO Mice Model Study Design 8 Day 2 weeks base line Injection 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Injection Injection Injection Injection OGTT (Day2) OGTT(Day 23 ) Glucose Insulin Cholesterol Body Composition Treatment (sc) Test Artic

  9. Slide 9: Once Weekly Administration Significantly Reduces Body Weight in DIO Mice

    Slide 9: Once Weekly Administration Significantly Reduces Body Weight in DIO Mice

    Once Weekly Administration of MOD - 6030 Significantly Reduces Body Weight in DIO Mice 9 30 35 40 45 50 55 60 65 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Body weight (g) Day - 1.6% - 16.6% - 27.6 % Effect of MOD - 6030 (Hydrolyzed Linker),

  10. Slide 10: Significant Advantages in Weight Reduction

    Slide 10: Significant Advantages in Weight Reduction

    MOD - 6030 Significant Advantages in Weight Reduction 10 Treatment Injection Frequency Dose per Injection Cumulative Dose in 30 Days Cumulative Weight Loss Day 30 (%) Cumulative Food Intake Reduction (%) Formulation Buffer 2x per Day -- -- 0.3% Gain -- OXM 2x per Day 6,000 nm 348,000 nm 16.6% Loss 1

  11. Slide 11: Induces Glucose Tolerance in DIO Mice

    Slide 11: Induces Glucose Tolerance in DIO Mice

    MOD - 6030 Induces Glucose Tolerance in DIO Mice 11 RS712 Part 4: Effect of PEG40-EMCS-OXM, PEG30-EMCS-OXM, PEG40-FMS-OXM, PEG30-FMS-OXM, OXM, liraglutide and sibutramine on glucose tolerance (2g/kg po) in male C57BL/6J mice which exhibit diet-induced obesity Male C57BL/6J mice were from Charles Riv

  12. Slide 12: Once Weekly Administration Improves Glycemic and Lipidic Profiles

    Slide 12: Once Weekly Administration Improves Glycemic and Lipidic Profiles

    Once Weekly Administration of MOD - 6030 Improves Glycemic and Lipidic Profiles 12 Terminal Glucose Terminal Cholesterol Terminal Insulin Terminal cholesterol A C E F G 0 50 100 150 200 250 PEG-SH (662 mg/kg) PEG30-EMCS-OXM (6000 nmol/kg) MOD-6030 (6000 nmol/kg) Vehicle (PBS bid) OXM (6000 nmol/kg b

  13. Slide 13: Conclusions

    Slide 13: Conclusions

    Conclusions • RevPEG was shown to be safe and tolerable in different toxicological rodent animal models. • RevPEG enables elongation of peptides’ half lives while maintaining their potential to penetrate target tissues (e.g. penetrate the BBB). • MOD - 6030 demonstrates superior long acting properti

  14. Slide 14: Thank You

    Slide 14: Thank You

    Thank You PROLOR BIOTECH Protein .Longevity. Redefined PROLOR BIOTECH

Source: SEC EDGAR · 8-K filed Apr 19, 2012

More decks from PROLOR Biotech Inc